WinRho SDF (rho(d) immune globulin (human)) / Kamada - LARVOL DELTA

A 5-YEAR QUALITY ASSESSMENT OF OUTPATIENT BLOOD PRODUCT TRANSFUSIONS IN PEDIATRIC PATIENTS:2014-2018 (ASPHO 2023) - "In the patients that spiked a fever, 1 patient received plts, 1 patient received RBCs, 1 patient received both RBCs and plts, and 1 patient received factor in the form of WinRho... The AE review demonstrates that outpatient blood product transfusion is safe and AE incidence of 0.46% is comparable to previously published benchmarks. Of note, the AE rate in pediatric patients is observed after all patients were pre-medicated. Although the AE percentage of 0.46% is low, it would be interesting to study platelet product characteristics such as the source, dose, duration of storage of platelets, and ABO matching status that might contribute to transfusion-related adverse events."

Clinical • Allergy • Infectious Disease • Pediatrics • Septic Shock

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma (clinicaltrials.gov) - P3 | N=53 | Completed | Sponsor: Children's Oncology Group | Active, not recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ Dec 2022

Trial completion • Trial completion date • Ataxia • CNS Tumor • Movement Disorders • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

Human immune globulin treatment controls Zika viremia in pregnant rhesus macaques. (PubMed, PLoS One) - "Hyperimmune globulin products such as VARIZIG and WinRho are FDA-approved to treat conditions during pregnancy such as Varicella Zoster virus infection and Rh-incompatibility. No adverse fetal or infant outcomes were identified in the treated animals, yet the placebo control treated animals also did not have signs related to congenital Zika syndrome (CZS). Human immune globulin may be a viable prophylaxis and treatment option for ZIKV infection during pregnancy, however, more studies are required to fully assess the impact of this treatment to prevent CZS."

Journal • Herpes Zoster • Infectious Disease • Varicella Zoster

Assessing Clinical Outcomes in Patients Undergoing Splenectomy for Immune Thrombocytopenia: A Real World Perspective (ASH 2021) - "Initial treatment consisted of steroids, IVIG (or WinRho), or both for all patients...Response rates for TPO-RA (8/11, 73%), danazol (2/3, 67%), and immunosuppressive therapy (1/1) were greater than that for rituximab infusion (4/11, 36%)... Our review of ITP splenectomies in a real world patient population revealed significant differences in treatment practices and timing of surgical intervention. We did not note differences in splenectomy outcomes across patients of different Backgrounds or with comorbidities, confirming that these should not play a role in treatment decisions. Patients who failed to respond to steroids and/or IVIG had lower response rates to splenectomy as has been previously hypothesized, though these represented a very small subset of our study population."

Clinical • Clinical data • Real-world evidence • Cardiovascular • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura